Earnings Summary

Everest Group Ltd’s revenue jumped 25.78% since last year same period to $4133Mn in the Q1 2024. On a quarterly growth basis, Everest Group Ltd has generated 12.95% jump in its revenue since last 3-months.

Everest Group Ltd’s net profit jumped 100.82% since last year same period to $733Mn in the Q1 2024. On a quarterly growth basis, Everest Group Ltd has generated -8.83% fall in its net profits since last 3-months.

Everest Group Ltd’s net profit margin jumped 59.67% since last year same period to 17.74% in the Q1 2024. On a quarterly growth basis, Everest Group Ltd has generated -19.29% fall in its net profit margins since last 3-months.

Everest Group Ltd’s price-to-earnings ratio after this Q1 2024 earnings stands at 5.68.

Everest Group Ltd’s earning per share (EPS) estimates for the current quarter stand at 16.82 - a 5.06% jump from last quarter’s estimates.

Everest Group Ltd’s earning per share (EPS) estimates for the current year stand at 16.82.

Everest Group Ltd’s earning per share (EPS) jumped 44.3% since last year same period to 16.32 in the Q1 2024. This indicates that the Everest Group Ltd has generated 44.3% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Everest Group Ltd’s return on assets (ROA) stands at 0.04.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Everest Group Ltd’s return on equity (ROE) stands at 0.25.

Everest Group Ltd declared 1.75 dividend per share during the earnings announcement for Q1 2024.